- Home
- TRNO vs SRRK Comparison
TRNO vs SRRK Comparison
Compare TRNO & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRNO | SRRK |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.8B |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TRNO | SRRK |
|---|---|---|
| Price | $74.97 | $52.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $67.83 | $56.17 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 103.65 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $476,383,000.00 | N/A |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $9.10 | $534.24 |
| P/E Ratio | $113.85 | ★ N/A |
| Revenue Growth | ★ 24.51 | N/A |
| 52 Week Low | $53.00 | $27.07 |
| 52 Week High | $75.23 | $58.49 |
Technical Indicators
Market Signals| Indicator | TRNO | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 77.05 | 51.66 |
| Support Level | $59.39 | $51.32 |
| Resistance Level | N/A | $58.49 |
| Average True Range (ATR) | 1.67 | 2.48 |
| MACD | 0.83 | -0.49 |
| Stochastic Oscillator | 72.32 | 30.08 |
Price Performance
Historical ComparisonAbout TRNO Terreno Realty Corporation
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.